Patents by Inventor Francesco Berti
Francesco Berti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190169216Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.Type: ApplicationFiled: February 13, 2019Publication date: June 6, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Paolo COSTANTINO, Maria Rosaria ROMANO, Francesco BERTI
-
Patent number: 10245310Abstract: The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 are Streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.Type: GrantFiled: August 5, 2015Date of Patent: April 2, 2019Assignee: GlaxoSmithKline Biologicals SAInventors: Francesco Berti, Roberta Cozzi, Domenico Maione, Cira Daniela Rinaudo, Immaculada Margarit Y Ros, Guido Grandi
-
Publication number: 20190060437Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.Type: ApplicationFiled: November 7, 2018Publication date: February 28, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
-
Patent number: 10188719Abstract: Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive amination of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.Type: GrantFiled: May 11, 2017Date of Patent: January 29, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventor: Francesco Berti
-
Patent number: 10172928Abstract: A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.Type: GrantFiled: December 17, 2015Date of Patent: January 8, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
-
Patent number: 10150979Abstract: The invention relates to bacterial mutants, particularly from Streptococcus agalactiae, that secrete capsular polysaccharide and methods of purifying the secreted bacterial capsular polysaccharides from culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.Type: GrantFiled: May 5, 2015Date of Patent: December 11, 2018Assignee: GlaxoSmithKline Biologicals SAInventors: Evita Balducci, Francesco Berti, Valdemar Robert Janulczyk, Immaculada Margarit Y Ros, Chiara Toniolo
-
Patent number: 10124051Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidizing a primary hydroxyl group in the capsular polysaccharide, to give an oxidized polysaccharide with an aldehyde group; and (b) coupling the oxidized polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.Type: GrantFiled: May 22, 2013Date of Patent: November 13, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
-
Publication number: 20180153983Abstract: The invention provides a process for preparing a conjugate of a S.aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.Type: ApplicationFiled: November 10, 2017Publication date: June 7, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Francesco BERTI, Paolo COSTANTINO, Maria Rosaria ROMANO
-
Publication number: 20180036402Abstract: A method of immunization against Group B Streptococcus infection, using an immunogenic composition conjugates of GBS capsular saccharide conjugated to carrier proteins.Type: ApplicationFiled: September 15, 2017Publication date: February 8, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERTI, Mario CONTORNI, Paolo COSTANTINO, Oretta FINCO, Guido GRANDI, Domenico MAIONE, John TELFORD
-
Patent number: 9839686Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.Type: GrantFiled: February 2, 2015Date of Patent: December 12, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
-
Publication number: 20170348408Abstract: A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.Type: ApplicationFiled: December 17, 2015Publication date: December 7, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERTI, Paolo COSTANTINO, Maria Rosaria ROMANO
-
Patent number: 9827301Abstract: Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodified native saccharides, derivatives of the invention are preferentially selected during conjugation to carrier proteins, and conjugates of the derivatives show improved immunogenicity compared to native polysaccharides.Type: GrantFiled: May 1, 2014Date of Patent: November 28, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Paolo Costantino, Francesco Berti
-
Patent number: 9803030Abstract: Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R1 (Ib) wherein X is C(O), S(O) or SO2; Y is NR1R2 or R3; R1 is C1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R2 is H or C1-6 alkyl; and R3 is C1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.Type: GrantFiled: January 11, 2008Date of Patent: October 31, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berti, Paolo Costantino, Alessandro Pianigiani
-
Publication number: 20170246285Abstract: Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive amination of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.Type: ApplicationFiled: May 11, 2017Publication date: August 31, 2017Inventor: Francesco Berti
-
Publication number: 20170224803Abstract: The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 are Streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.Type: ApplicationFiled: August 5, 2015Publication date: August 10, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERTI, Roberta COZZI, Domenico MAIONE, Cira Daniela RINAUDO, Immaculada MARGARIT Y ROS, Guido GRANDI
-
Patent number: 9675691Abstract: Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive amination of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.Type: GrantFiled: May 8, 2015Date of Patent: June 13, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Francesco Berti
-
Publication number: 20170073716Abstract: The invention relates to bacterial mutants, particularly from Streptococcus agalactiae, that secrete capsular polysaccharide and methods of purifying the secreted bacterial capsular polysaccharides from culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.Type: ApplicationFiled: May 5, 2015Publication date: March 16, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Evita BALDUCCI, Francesco BERTI, Valdemar Robert JANULCZYK, Immaculada MARGARIT Y ROS, Chiara TONIOLO
-
Patent number: 9562894Abstract: Methods for detecting in a sample the presence of an antibody to a conjugate of an antigen associated with a first carrier by a first association are disclosed. The method comprises contacting a conjugate of the antigen associated with a second carrier by a second association with said sample under conditions that allow binding of the antibody to the antigen; and introducing an agent to detect the presence of the antibody bound to said antigen. The first association and the second association are covalent associations and the first association is different from the second association. Also provided are kits, multiwell plates and conjugates that are useful in the method and further uses of the method. Also provided is a method of releasing a batch of a vaccine comprising a conjugate of an antigen associated with a first carrier by a first association and antibodies useful in this method.Type: GrantFiled: December 12, 2012Date of Patent: February 7, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berti, Carl E. Frasch
-
Publication number: 20160376301Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.Type: ApplicationFiled: September 7, 2016Publication date: December 29, 2016Applicant: GlaxoSmithKline Biologicals SAInventors: Paolo COSTANTINO, Maria Rosaria ROMANO, Francesco BERTI
-
Patent number: 9475846Abstract: Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM197 (a non-toxic variant of diphtheria toxin) and tetanus toxoid, as carrier proteins.Type: GrantFiled: October 26, 2012Date of Patent: October 25, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Francesca Micoli, Francesco Berti, Paolo Costantino